Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hocanalysis of the Engage trial

被引:0
|
作者
Arthur Leader
Paul Devroey
Han Witjes
Keith Gordon
机构
[1] University of Ottawa,The Ottawa Fertility Centre, Division of Reproductive Medicine
[2] Universitair Ziekenhuis Brussel,Center for Reproductive Medicine
[3] MSD Oss B.V.,undefined
[4] Oss,undefined
[5] Merck Sharp & Dohme Corp,undefined
来源
Reproductive Biology and Endocrinology | / 11卷
关键词
Protocol flexibility; Controlled ovarian stimulation; Corifollitropin alfa; Recombinant follicle stimulating hormone;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [31] Elevated progesterone (>1.5 ng/mL) during the late follicular phase of ovarian stimulation with corifollitropin alfa or rFSH does not compromise pregnancy rates in older women
    Kutteh, W.
    Shapiro, B.
    Witjes, H.
    Gordon, K.
    HUMAN REPRODUCTION, 2013, 28 : 345 - 346
  • [32] INCIDENCE OF CONGENITAL MALFORMATIONS AFTER OVARIAN STIMULATION WITH CORIFOLLITROPIN ALFA OR RECOMBINANT FSH: DATA FROM 3 RANDOMIZED CONTROLLED TRIALS
    Stegmann, B.
    Bonduelle, M.
    Gordon, K.
    Witjes, H.
    Verweij, P.
    FERTILITY AND STERILITY, 2013, 100 (03) : S59 - S59
  • [33] Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa
    Griesinger, Georg
    Teal, Valerie
    Sisk, Christine McCrary
    Ruman, Jane
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2019, 232 : 101 - 105
  • [36] Corifollitropin alfa followed by hp-HMG versus recombinant FSH in young poor ovarian responders: a multicenter randomized controlled clinical trial
    Drakopoulos, P.
    Vuong, N. L.
    Ho, N. A. V.
    Vaiarelli, A.
    Ho, M. T.
    Blockeel, C.
    Camus, M.
    Lam, A. T.
    Van de Vijver, A.
    Humaidan, P.
    Tournaye, H.
    Polyzos, N. P.
    HUMAN REPRODUCTION, 2017, 32 : 6 - 7
  • [37] Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial
    Drakopoulos, Panagiotis
    Thi Ngoc Lan Vuong
    Ngoc Anh Vu Ho
    Vaiarelli, Alberto
    Manh Tuong Ho
    Blockeel, Christophe
    Camus, Michel
    Anh Tuan Lam
    van de Vijver, Arne
    Humaidan, Peter
    Tournaye, Herman
    Polyzos, Nikolaos P.
    HUMAN REPRODUCTION, 2017, 32 (11) : 2225 - 2233
  • [38] Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial
    De Placido, G
    Alviggi, C
    Perino, A
    Strina, I
    Lisi, F
    Fasolino, A
    De Palo, R
    Ranieri, A
    Colacurci, N
    Mollo, A
    HUMAN REPRODUCTION, 2005, 20 (02) : 390 - 396
  • [39] A LARGE DOUBLE-BLIND EFFICACY AND SAFETY TRIAL OF CORIFOLLITROPIN ALFA VERSUS DAILY RECOMBINANT FSH IN WOMEN 35 TO 42 YEARS OF AGE UNDERGOING OVARIAN STIMULATION PRIOR TO IVF OR ICSI (PURSUE TRIAL)
    Boostanfar, R.
    Yeko, T.
    Shapiro, B.
    Elbers, J.
    Witjes, H.
    Mannaerts, B.
    FERTILITY AND STERILITY, 2012, 98 (03) : S34 - S34
  • [40] Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: a multi-center randomized controlled trial
    Shu, Li
    Xu, Qianhua
    Meng, Qingxia
    Dai, Xue
    Zhang, Yun
    Zhou, Wei
    Yi, Honggang
    Liu, Jinyong
    Wu, Chunxiang
    Hou, Zhen
    Cui, Yugui
    Li, Tin Chiu
    Liu, Jiayin
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (07)